Pluristem Therapeutics to Sponsor the World Conference on Regenerative Medicine
NEW YORK, Apr 07, 2009 (BUSINESS WIRE) -- Pluristem Therapeutics Inc. (NasdaqCM:PSTI)(DAX:PJT), a bio-therapeutics company dedicated to the commercialization of unrelated donor-patient (allogeneic) cell therapy products for a variety of disorders, announced today that it will be sponsoring the World Conference on Regenerative Medicine to be held on October 29-31, 2009 in Leipzig, Germany. The conference, which will be organized by the Fraunhofer Institute for Cell Therapy and Immunology, will provide a platform for the exchange of information on stem cells, tissue engineering, technology development such as bioreactors, immunology signaling and regulatory topics.
"Pluristem is honored to sponsor the World Conference of Regenerative Medicine", stated Zami Aberman, Chairman, President and CEO of Pluristem. "This conference presents the current science on the threshold of cell therapy, and we at Pluristem believe that cell therapy will give patients a better chance", he added.
Prof. Dr. Frank Emmrich, Director of the Institute for Clinical Immunology and Transfusion Medicine, University of Leipzig, Germany,stated, "We are pleased that Pluristem continues to sponsor the World Conference on Regenerative Medicine. Pluristem's involvement reflects its continuous commitment to the field of bio-therapy as well as the Company's acknowledgment of the significance of the German scientific institutions in Leipzig."
wcrm-leipzig.com
About Fraunhofer Institute for Immunology and Cell Therapy
The objective of the Fraunhofer Institute for Immunology and Cell Therapy (IZI) is to find solutions to specific problems at the interfaces between medicine, life sciences and engineering for partners active in medicine-related industries and businesses. The Institute's core competencies are found in regenerative medicine, or more precisely in cell-therapeutic methods of regenerating non-functioning tissue and organs through to biological substitution with tissue cultivated in vitro (tissue engineering). In order for the living organism to accept these tissues without difficulty, it is necessary to study cellular and immunological defense and control mechanisms and take these into account during the process product development. These core competencies entail a multiplicity of tasks to be solved by new products and processes. |
